Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Spinal muscular atrophy diagnostics.

Thomas W Prior1

  • 1Department of Pathology, Ohio State University, Columbus, Ohio 43210, USA. thomas.prior@osumc.edu

Journal of Child Neurology
|September 1, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical <i>SMN1</i> and <i>SMN2</i> Gene-Specific Sequencing to Enhance the Clinical Sensitivity of Spinal Muscular Atrophy Diagnostic Testing.

Human mutation·2025
Same author

Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.

Leukemia·2022
Same author

Characterization of Prion Disease Associated with a Two-Octapeptide Repeat Insertion.

Viruses·2021
Same author

Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results.

Leukemia·2021
Same author

Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative.

JCO precision oncology·2021
Same author

Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.

Leukemia·2021

Spinal muscular atrophy (SMA) is a genetic neuromuscular disorder caused by SMN gene mutations. SMN1 exon 7 absence is common in SMA, while SMN2 copy number influences disease severity.

Area of Science:

  • Genetics
  • Neuromuscular Disorders
  • Molecular Biology

Background:

  • Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder.
  • Mutations in the survival motor neuron gene (SMN) cause SMA.
  • SMN exists as two similar copies: SMN1 and SMN2.

Purpose of the Study:

  • To investigate the genetic basis of Spinal Muscular Atrophy (SMA).
  • To understand the role of SMN1 and SMN2 gene copies in SMA.
  • To evaluate SMN1 dosage testing for SMA diagnosis and carrier detection.

Main Methods:

  • Analysis of SMN gene mutations, focusing on exon 7.
  • SMN1 dosage testing to determine gene copy number.
  • Investigation of small mutations in the 3' end of SMN1.

Related Experiment Videos

  • Assessment of SMN2 copy number's effect on SMA phenotype.

    • Main Results:

    • Homozygous absence of SMN1 exon 7 is found in ~95% of SMA patients.
    • Small mutations in SMN1's 3' end account for the remaining 5% of SMA cases.
    • SMN1 dosage testing can identify carriers and compound heterozygotes, though accuracy is affected by 2 SMN1 copies per chromosome in ~2% of carriers.
    • SMN2 copy number influences SMA phenotype severity.

    Conclusions:

    • SMN1 mutations are the primary cause of Spinal Muscular Atrophy.
    • SMN1 dosage testing is a valuable diagnostic tool, but limitations exist.
    • SMN2 copy number is a critical modifier of SMA disease presentation.